Actavis Launches U.S. Generic Specialty Injectable Portfolio
Actavis will immediately begin marketing approximately 20 injectable products across a number of therapeutic categories in the U.S. The Company will be a leader in Oncology, with nearly a dozen marketed products including generic versions of Gemzar, Taxotere, Campostar and Zometa. Actavis also has an industry leading specialty injectable pipeline, with approximately 20 new filings under review at the U.S. Food and Drug Administration (FDA), as well as more than 50 additional projects currently in development.
Many of Actavis’ generic specialty injectable products were previously marketed in the U.S. by Sagent Pharmaceuticals, Inc. under a manufacturing and supply agreement originally signed by the companies in 2010. Actavis regained U.S. marketing rights to the products following the expiration of the Sagent agreement on December 31, 2014.
Over the last several years, we have been steadily growing our generic specialty injectable business around the world, marketing products in more than 50 countries. With the addition of this diverse portfolio of injectable products to our U.S. portfolio, we will create a leading specialty injectable business within Actavis and immediately become a strong competitor in this important, high-value space. In addition, we will continue to invest in the development of our industry-leading generic injectable pipeline as part of our strategy to drive growth through complex, high-barrier-to-entry products. With our proven, well-established supply chain, experience in hospital sales from our brand anti-infective portfolio and strong existing customer relationships, our specialty injectable business is positioned to be a strong growth driver for our Company going forward
Related Articles
About Actavis
Actavis plc, headquartered in Dublin, Ireland, is a unique specialty pharmaceutical company focused on developing, manufacturing and commercializing high quality affordable generic and innovative branded pharmaceutical products for patients around the world.
Actavis markets a broad portfolio of branded and generic pharmaceuticals and develops innovative medicines for patients suffering from diseases principally in the central nervous system, gastroenterology, women’s health, urology, cardiovascular, respiratory and anti-infective therapeutic categories. The company is an industry leader in product research and development, with one of the broadest brand development pipelines in the pharmaceutical industry, and a leading position in the submission of generic product applications. Actavis has commercial operations in more than 60 countries and operates more than 30 manufacturing and distribution facilities around the world.
Related Articles
About Post Author
